Open-label, Randomized, 2-arm, Active Comparator Study to Evaluate Safety and Tolerability in Portuguese Patients with Relapsing Remitting Multiple Sclerosis (MS) Transitioning from Standard-of-care Subcutaneous Interferon Therapy to Peginterferon Beta 1a (PLEGRIDY™)